Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
29.71%
Net Margin
30.08%
Efficiency Metrics
Revenue per Expense Ratio
1.89
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
40.68%
Income Tax Rate
18.79%
EPS
1.4900000000
Balance Sheet Analysis
Current Ratio
0.06
Cash Ratio
0.46
Working Capital
$-19.05B
Debt to Equity
0.45
Debt to Assets
4.95%
Equity Ratio
11.02%
Cash Flow Analysis
Operating Cash Flow Ratio
41.85%
Free Cash Flow Ratio
40.61%
CapEx to Revenue
1.24%
Dividends Paid
$367.00M
Stock Buybacks
$10.00M
Total Shareholder Returns
$377.00M
Cash Position Change
12.18%
Key Takeaways (2023 FY)
Revenue declined by 7.0738547834216%, indicating potential market challenges
Detailed Growth Metrics
Core Performance
Revenue
-7.07%
Net Income
-0.33%
EPS
-8.02%
Operating Income
-38.94%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
21.89%
Operating Cash Flow
-43.79%
Free Cash Flow
-44.72%
Balance Sheet Health
Assets
3.43%
Debt
-1.44%
Book Value per Share
-0.16%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-5.31%
Shares Outstanding
8.87%
Long Term Trends
3Y Revenue/Share
-29.86%
5Y Revenue/Share
-11.99%
3Y Dividend/Share
13.92%
5Y Dividend/Share
41.04%